GLP-1 medications provide important safety information on their websites, including possible side effects from taking the drug
Mode of Failure: Physical Stability For low water activity (0.20-0.40 aw) products such as snacks, dry pet food, and food powders, chemical reactions and microbial contamination are not the most likely modes of failure
Early trials have provided implication of the neuroprotective benefits of pioglitazone, which are potentially mediated by its anti-inflammatory and insulin-sensitizing effects
GLP 1 medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, known hypersensitivity to semaglutlutide, or during pregnancy
FDA is aware of some instances in which patients have been given syringes that are significantly larger than the prescribed volume of semaglutide (see example in Figure 1)
Beyond-use date testing